FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296817009> ?p ?o ?g. }

• W4296817009 endingPage "e805" @default.
• W4296817009 startingPage "e804" @default.
• W4296817009 abstract "I read with interest the Editorial in The Lancet Haematology describing the interim report of the UK's Infected Blood Inquiry.1The Lancet HaematologyUK Infected Blood Inquiry: long-awaited progress?.Lancet Haematol. 2022; 9: e627Summary Full Text Full Text PDF PubMed Google Scholar The Editorial correctly noted that the contaminated blood scandal “spurred the creation” of Canadian Blood Services. It is a tragic history that has shaped and guided our organisation. I too assert that individuals affected by this history deserve justice. The mistakes of the past must not be repeated. However, I would like to address two inaccuracies. The Editorial stated that “paid-for systems are widely regarded as being less safe than those in which blood is altruistically given”.1The Lancet HaematologyUK Infected Blood Inquiry: long-awaited progress?.Lancet Haematol. 2022; 9: e627Summary Full Text Full Text PDF PubMed Google Scholar This is misleading. Modern technology has made plasma products safe, regardless of whether the donor is provided an incentive. There has not been a single case of transmission of hepatitis B, hepatitis C, or HIV through plasma products in several decades. The Editorial also noted “it was recently announced that the plasma collection [of Canadian Blood Services] is to be sold to a foreign pharmaceutical company and turned into a for-profit system”.1The Lancet HaematologyUK Infected Blood Inquiry: long-awaited progress?.Lancet Haematol. 2022; 9: e627Summary Full Text Full Text PDF PubMed Google Scholar This is fundamentally incorrect. Canadian Blood Services has announced a plan to increase and protect the supply of plasma for immunoglobulins in Canada. These actions are informed by a risk-based decision-making analysis2Canadian Blood ServicesPlasma and immunoglobulin security of supply: risk-based decision-making analysis.https://www.blood.ca/sites/default/files/Plasma_and_Immunoglobulin_Security_of_Supply_-_RBDM_Analysis_2022_-_Public_Final.pdfDate: June, 2022Date accessed: September 16, 2022Google Scholar that generated recommendations for collaborative action across the broader blood supply system, including to act with urgency and leverage both not-for-profit and commercial sectors. The plan includes an agreement with Grifols, a global leader in producing plasma medicines. Under the agreement, both Canadian Blood Services and Grifols will collect plasma that will be manufactured into immunoglobulins for patients in Canada. Purchasing immunoglobulins from the commercial plasma sector has been part of the organisation's practice for more than two decades. This agreement provides essential protections for the national blood supply system, including controls to prevent negative effects on our current and future network of blood and plasma donor centres; ensures plasma donated in Canada is used to make immunoglobulins in Canada, for patients in Canada; and enables a domestic end-to-end supply chain for immunoglobulins. The agreement does not involve the sale of any aspect of the national system and does not change the activities of Canadian Blood Services. Plasma and plasma products will remain a public resource in Canada, ensuring immunoglobulins remain available for patients in Canada. These are responsible actions for the blood operator to take, given its mandate to ensure security of supply of blood and plasma products for Canada. I declare no competing interests. UK Infected Blood Inquiry: long-awaited progress?On July 29, 2022, an interim report of the UK's Infected Blood Inquiry recommended to the government that an interim payment of no less than £100 000 should be paid to all individuals infected by contaminated blood in the 1970s and 1980s, or their bereaved partners. These infections were the result of the UK importing clotting factor and other blood products from sources where the plasma used in manufacturing came from donors who sold their blood, primarily in the USA, when it was unable to keep up with demand for clotting factors. Full-Text PDF" @default.
• W4296817009 created "2022-09-24" @default.
• W4296817009 creator A5046891036 @default.
• W4296817009 date "2022-11-01" @default.
• W4296817009 modified "2023-09-30" @default.
• W4296817009 title "Blueprint for greater security of immunoglobulins for patients in Canada" @default.
• W4296817009 cites W4293708380 @default.
• W4296817009 doi "https://doi.org/10.1016/s2352-3026(22)00317-9" @default.
• W4296817009 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36162416" @default.
• W4296817009 hasPublicationYear "2022" @default.
• W4296817009 type Work @default.
• W4296817009 citedByCount "0" @default.
• W4296817009 crossrefType "journal-article" @default.
• W4296817009 hasAuthorship W4296817009A5046891036 @default.
• W4296817009 hasBestOaLocation W42968170091 @default.
• W4296817009 hasConcept C127413603 @default.
• W4296817009 hasConcept C155911762 @default.
• W4296817009 hasConcept C17744445 @default.
• W4296817009 hasConcept C199539241 @default.
• W4296817009 hasConcept C2776957806 @default.
• W4296817009 hasConcept C71924100 @default.
• W4296817009 hasConcept C78519656 @default.
• W4296817009 hasConceptScore W4296817009C127413603 @default.
• W4296817009 hasConceptScore W4296817009C155911762 @default.
• W4296817009 hasConceptScore W4296817009C17744445 @default.
• W4296817009 hasConceptScore W4296817009C199539241 @default.
• W4296817009 hasConceptScore W4296817009C2776957806 @default.
• W4296817009 hasConceptScore W4296817009C71924100 @default.
• W4296817009 hasConceptScore W4296817009C78519656 @default.
• W4296817009 hasIssue "11" @default.
• W4296817009 hasLocation W42968170091 @default.
• W4296817009 hasLocation W42968170092 @default.
• W4296817009 hasOpenAccess W4296817009 @default.
• W4296817009 hasPrimaryLocation W42968170091 @default.
• W4296817009 hasRelatedWork W2436694896 @default.
• W4296817009 hasRelatedWork W2469282801 @default.
• W4296817009 hasRelatedWork W2487906736 @default.
• W4296817009 hasRelatedWork W2555443816 @default.
• W4296817009 hasRelatedWork W2804386710 @default.
• W4296817009 hasRelatedWork W3085278910 @default.
• W4296817009 hasRelatedWork W3165817088 @default.
• W4296817009 hasRelatedWork W4381094120 @default.
• W4296817009 hasRelatedWork W1918510473 @default.
• W4296817009 hasRelatedWork W217308065 @default.
• W4296817009 hasVolume "9" @default.
• W4296817009 isParatext "false" @default.
• W4296817009 isRetracted "false" @default.
• W4296817009 workType "article" @default.